Phase 3 N=30 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan Syndrome
Primary: Central Aortic Distensibility by MRI — 3.7; 4.7; 5.7; 5.1 (mmHg ^ -1) x 10 ^ -3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=149 Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
Phase 3 N=40 Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
Phase 4 N=20 Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis
Aortic Stenosis
Primary: Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort. — -25 percent change
N/A N=50 Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography
Aortic Stenosis
Primary: Aortic Stenosis Acceleration Index Compared to Aortic Stenosis Severity — 21; 8; 1; 6 participants
N/A N=1,453 Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement
Severe Aortic Stenosis
Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 26.0; 39.3; 14.1; 18.9 percentage of participants, Kaplan-Meier — p=<0.0001
N/A N=259 Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)
Lumbar Spinal Stenosis
Primary: Swiss Spinal Stenosis (SSS) Questionnaire Score — -2.0; -1.7; -4.1 units on a scale — p=0.73
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
Phase 3 N=231 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
N/A N=2,777 Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
Severe Aortic Stenosis
Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 22.5; 30.8; 17.8 percentage of participants, Kaplan-Meier
Phase 2 N=23 A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
Aortic Valve Stenosis
Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05
N/A N=20 Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis
Aortic Valve Stenosis
Primary: Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA). — 75.0; 87.5 percentage of participants analyzed — p=0.002
N/A N=60 Hemodynamic Comparison of Tissue Aortic Valves
Aortic Valve Stenosis
Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg
N/A N=20 HAART 200 Aortic Valve Annuloplasty Trial
Aortic Insufficiency
Primary: Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure. — 100 percentage of participants